Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 72Neoplasms 64Prostatic Neoplasms 45Colorectal Neoplasms 42Lung Neoplasms 38Carcinoma, Non-Small-Cell Lung 26Pancreatic Neoplasms 21Neoplasm Metastasis 20Hematologic Neoplasms 20Head and Neck Neoplasms 20Urinary Bladder Neoplasms 15Ovarian Neoplasms 14Multiple Myeloma 11Motor Activity 11Leukemia, Myeloid, Acute 11Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Uterine Cervical Neoplasms 9Triple Negative Breast Neoplasms 9Glioblastoma 9Colonic Neoplasms 9Hematopoietic and Lymphatic System Neoplasm 8Glioma 8Gastrointestinal Neoplasms 8Carcinoma, Renal Cell 8COVID-19 8Anxiety Disorders 8Anatomic Stage I Breast Cancer AJCC v8 8Rectal Neoplasms 7Melanoma 7

Interventions

Mitomycin 3vofatamab 2pembrolizumab 2Standard of Care 2B701 protein, Human herpesvirus 6 2valrubicin 1trifluridine tipiracil drug combination 1testosterone 17 beta-cypionate 1palbociclib 1enfortumab vedotin 1atezolizumab 1Water 1Valsartan 1Urinary Diversion 1Tranexamic Acid 1Testosterone Propionate 1Sunitinib 1Stents 1Radiosurgery 1Radiation Dose Hypofractionation 1Practice Guidelines as Topic 1Nephrotomy 1Nephrostomy, Percutaneous 1Methyltestosterone 1Immune Checkpoint Inhibitors 1Ice 1Hydroxychloroquine 1Health Information Exchange 1Gemcitabine 1Gels 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Urologic Diseases × Standard of Care × Clear all
NCT04731376 2026-05-26

Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone

Emory University

Phase 1 Active not recruiting
56 enrolled
Genitourinary

Hypogonadism, Urologic Diseases, Urologic Neoplasms

NCT01310803 2017-10-05

Multi-center Study to Evaluate the Efficacy and Safety of Maintenance Therapy With Valrubicin Versus no Maintenance, in Subjects Treated With Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder

Endo Pharmaceuticals

Phase 3 Terminated
1 enrolled 5 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡